![li su chinese font free download li su chinese font free download](https://pic.chinesefontdesign.com/uploads/2015/06/u678.png)
The objective response rate (ORR) of this treatment can reach more than 70%, which brings clinical benefits to ROS1-positive advanced NSCLC. 3, 4Ĭurrently, two targeted drugs, crizotinib and entrectinib, have been approved by FDA for the treatment of patients with ROS1 fusion, while the current development of ROS1 inhibitors is still relatively limited. 2 When ROS1 fuses with other genes, the kinase domain was usually retained and would activate signaling pathways that are critical to the occurrence and progression of cancer, such as PI3K/AKT/mTOR and JAK/STAT pathway. ROS1 gene can rearrange with multiple genes, and the most frequent fusion partner is CD74.
#Li su chinese font free download driver#
1 The incidence of ROS1 fusion is mainly concentrated in younger Asian patients with no smoking history and histological type of adenocarcinoma, and it rarely coexists with other driver gene mutations. ROS1 fusion gene is detected in cancer patient with a certain mutation rate and incidence (1–2%). With the wide application of next-generation sequencing (NGS) technology in clinical practice, more and more rare fusion variant type has been found in non-small cell lung cancer (NSCLC). Keywords: BAIAP2-ROS1 fusion, advanced lung adenocarcinoma, sensitive to crizotinib, next-generation sequencing The good response to crizotinib therapy emphasizes the importance of DNA-based and RNA-based NGS in rare fusion identification in clinical practice. The patient subsequently received crizotinib and showed significant tumor reduction until 17 months, who got benefit from targeted therapy.Ĭonclusion: This study discovered a novel BAIAP2-ROS1 rearrangement it provides more knowledge of ROS1 fusion in clinical personalized treatment.
![li su chinese font free download li su chinese font free download](https://pic.chinesefontdesign.com/uploads/2013/01/Mini-Xiao-sha-Font-Simplified-Chinese.jpg)
A complete kinase domain in ROS1 fusion was preserved. Rearrangement consisted of BAIAP2 in exon1-exon13 of chr17: q23 and ROS1 in exon35-exon43 of chr6: q22, which were further confirmed by RNA-based NGS methodology. Results: Using DNA-targeted NGS method, we identified a novel BAIAP2-ROS1 fusion in a 71-year-old non-smoking female patient with stage IVB lung adenocarcinoma. RNA fusion panel based on hybrid capture sequencing was performed to verify gene fusions from total RNA which isolated from formalin fixed paraffin-embedded (FFPE) tissue blocks. Materials and Methods: Deep-coverage targeting solid tumor 31 cancer-related genes panel was used to capture DNA-based NGS information to detect gene fusion.
![li su chinese font free download li su chinese font free download](https://pic.chinesefontdesign.com/uploads/2020/12/chinesefontdesign.com-2020-12-08-08-58-15-19.jpg)
Therefore, it is important to accurately identify the type of ROS1 rearrangement in NSCLC for clinical treatment selection. Objective: Previous studies have shown that fusion partners have a potential role in influencing different tumorigenic abilities of ROS1 fusion variants, as well as potential differential responses to crizotinib. *These authors contributed equally to this workĬorrespondence: Qiqi Tian Wendy Wu, Email It does not store any personal data.YunYu Lin, 1, * Yan Lei, 2, * LinWei Li, 2 Xiaoxing Su, 2 Qiqi Tian, 1 Wendy Wu 2ġRespiratory Medicine, NingHai First Hospital, NingBo, 315600, People’s Republic of China 2Berry Oncology Institutes, Berry Oncology Corporation, Fuzhou, 350200, People’s Republic of China The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly.